GlassScriptPhysician profile
Michael G Grill
NPI 1962490110
$18,343.50
in general payments reported to CMS, 2019-2025
36 companies · $3,332 in 2025
The $3,332 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,536 · 2020: $1,679 · 2021: $2,335 · 2022: $2,887 · 2023: $3,231 · 2024: $3,345 · 2025: $3,332.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,907.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,907.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,226.85 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $2,626.80 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Novo Nordisk INC | $1,998.68 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,992.90 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $1,733.45 | 2020-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,297.26 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $819.43 | 2019-2025 | Jardiance, Glyxambi, Synjardy |
| Amarin Pharma, INC. | $680.45 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $487.46 | 2019-2023 | Steglatro |
| Allergan, INC. | $367.44 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $357.58 | 2019-2024 | Livalo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $339.14 | 2020-2025 | Xifaxan |
| Madrigal Pharmaceuticals | $272.52 | 2024-2025 | Rezdiffra |
| Pfizer INC. | $245.30 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $198.90 | 2022-2023 | Xarelto |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $183.08 | 2019-2025 | Repatha, Otezla, Repatha |
| Abbott Laboratories | $157.36 | 2023-2024 | Freestyle Libre |
| Sanofi-Aventis U.S. LLC | $142.48 | 2019-2022 | |
| Corcept Therapeutics | $139.87 | 2025 | Korlym |
| Avanir Pharmaceuticals, INC. | $139.78 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $120.25 | 2019-2022 | |
| Antares Pharma, INC. | $119.96 | 2025 | Xyosted |
| Idorsia Pharmaceuticals US INC | $88.44 | 2022-2023 | Quviviq |
| Medtronic, INC. | $81.35 | 2024-2025 | Intellis Adaptivestim |
| Teva Pharmaceuticals USA, INC. | $78.69 | 2021 | |
| Arbor Pharmaceuticals, INC. | $70.28 | 2020-2022 | |
| Endo Pharmaceuticals INC. | $60.07 | 2020 | |
| Apria Healthcare LLC | $54.43 | 2021 | |
| Exact Sciences Corporation | $49.65 | 2023-2024 | Cologuard Collection Kit |
| Amneal Pharmaceuticals LLC | $42.24 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $35.60 | 2019 | |
| Shield Therapeutics INC | $35.15 | 2025 | |
| Ibsa Pharma INC. | $33.09 | 2020-2021 | |
| Qol Medical, LLC | $23.69 | 2025 | Sucraid |
| Sanofi Pasteur INC. | $23.66 | 2023 | |
| Azurity Pharmaceuticals, INC. | $20.22 | 2023 | Edarbyclor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Grill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.